The retail sector delivered a mixed performance during the festive season, with select pockets emerging as bright spots, ...

Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ...

Dr. Reddys Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the ...

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...

Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...

Mixed Q3FY25 outlook for retail industry with jewellery and value retail leading growth, footwear and apparel showing ...

Niftys earnings per share (EPS) expected by a modest 2 per cent year-on-year (YoY) in the third quarter of FY25, according to ...

Sagar Doshi of Nuvama Professional Clients Group recommends these three stocks today- Oil and Natural Gas Corporation Ltd ...

Nuvama maintains a defensive portfolio, overweight in private banks, insurance, and sectors like pharma and cement, while ...

Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026.

OrbiMed-backed Laxmi Dental on Wednesday said it has fixed the price band at ₹407-428 per share for ₹698 crore initial public ...

Domestic passive mutual fund (MF) schemes will have to sell around Rs 1,500 crore worth of ITC Hotels shares once the ...